Abstract: The present invention is directed to a method of modulating inflammation and/or related complications triggered by ZAK? kinase-activated NLRP1-driven pyroptosis; a compound or composition comprising said compound for use in the method, and use of said compounds in medicament preparation. More particularly, the inflammation is caused by a ribotoxin or UVB irradiation. Inhibition of said ZAK? kinase-activated NLRP1-driven pyroptosis may be used in the prophylaxis or treatment of human airway or skin inflammation and/or related complications, whereas activation of ZAK? kinase-activated NLRP1-driven pyroptosis may be used in the prophylaxis or treatment of cancer.

Abstract: A Ni—Al2O3@Al2O3—SiO2 catalyst with coated structure is provided. The catalyst has a specific surface area of 98 m2/g to 245 m2/g, and a pore volume of 0.25 cm3/g to 1.1 cm3/g. A mass ratio of an Al2O3 carrier to active component Ni in the catalyst is Al2O3:Ni=100:4˜26, a mass ratio of the Al2O3 carrier to an Al2O3—SiO2 coating layer is Al2O3:Al2O3—SiO2=100:0.1˜3, and a molar ratio of Al to Si in the Al2O3—SiO2 coating layer is 0.01 to 1. Ni particles are distributed on a surface of the Al2O3 carrier in an amorphous or highly dispersed state and have a grain size less than or equal to 8 nm, and the coating layer is filled among the Ni particles.

Abstract: A Ni—Al2O3@Al2O3—SiO2 catalyst with coated structure is provided. The catalyst has a specific surface area of 98 m2/g to 245 m2/g, and a pore volume of 0.25 cm3/g to 1.1 cm3/g. A mass ratio of an Al2O3 carrier to active component Ni in the catalyst is Al2O3:Ni=100:4˜26, a mass ratio of the Al2O3 carrier to an Al2O3—SiO2 coating layer is Al2O3:Al2O3—SiO2=100:0.1˜3, and a molar ratio of Al to Si in the Al2O3—SiO2 coating layer is 0.01 to 1. Ni particles are distributed on a surface of the Al2O3 carrier in an amorphous or highly dispersed state and have a grain size less than or equal to 8 nm, and the coating layer is filled among the Ni particles.